Celecoxib Inhibits Cellular Growth, Decreases Ki-67 Expression and Modifies Apoptosis in Ovarian Cancer Cell Lines

Archives of Medical Research

Volumn 37, Issue 6, 2006, Pages 689-695

  Vital Reyes, Víctor ^a,b   Rodríguez Burford, Cristina ^a   Chhieng, David C ^a   Oelschlager, Denise K ^a   Reyes Fuentes, Alejandro ^c   Barnes, Mack ^b   Grizzle, William E ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Celecoxib; Cellular growth; Ovarian cancer

Indexed keywords

CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; KI 67 ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NICK END LABELING; OVARY CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CASPASE 3; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; OVARIAN NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 33745648487     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2005.11.014     Document Type: Article

References (24)

1. Ovarian Cancer. In the Early Detection Research Network. Translational Research to Identify Early Cancer and Cancer Risk. National Cancer Institute. NIH-Publication No. 02-5216. Second Report, October 2002. pp. 21-23.
2. Cannistra S.A. Cancer of the ovary. NEJM 351 (2004) 2519-2529
3. Barnes M.N., Grizzle W.E., Grubbs C.J., and Partridge E.E. Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin 52 (2002) 216-225
4. Dannenberg A.J., and Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 (2003) 431-436
5. Thun M.J., Heneley J.S., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
6. Kiefer W., and Dannhardt G. Novel insights and therapeutical applications in the field of inhibitors of COX-2. Curr Med Chem 11 (2004) 3147-3161
7. Zha S., Yegnasubramanian V., Nelson W.G., Isaacs W.B., and DeMarzo A.M. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215 (2004) 1-20
8. Akhmeddkhanov A., Toniolo P., Zeleniuch-Jacquotte A., Kato I., Koenig K.L., and Shore R.E. Aspirin and epithelial ovarian cancer. Prevent Med 33 (2002) 682-687
9. Moysich K.B., Mettlin C., Piver M., Natarajan N., Menezes R.J., and Swede W. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 10 (2001) 903-906
10. Rodriguez-Burford C., Barnes M.N., Oelschlager D.K., Myers R.B., Talley L.I., Partridge E.E., et al. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8 (2002) 202-209
11. Rodriguez-Burford C., Oelschlager D.K., Talley L.I., Barnes M.N., Partridge E.E., and Grizzle W.E. The use of dimethylsulfoxide as a vehicle in cell culture experiments using ovarian carcinoma cell lines. Biotech Histochem 78 (2003) 17-21
12. Grizzle W.E., Myers R.B., Manne U., and Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M., and Walazek Z. (Eds). John Walker's Methods in Molecular Medicine-Tumor Marker Protocols (1998), Humana Press, Totowa, NJ 143-160
13. Grizzle W.E., Shibata D., Manne U., Myers R.B., and Frost A.R. Molecular and histopathologic changes in the development of colorectal neoplasia. In: Srivastava S., et al. (Ed). Molecular Pathology of Early Cancer (1999), IOS Press, Amsterdam 135-170
14. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227 (1970) 680-685
15. Myers R.B., Srivastava S., Oelschlager D.K., and Grizzle W.E. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86 (1994) 1140-1145
16. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrilamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76 (1979) 4350-4354
17. Schluter C., Duchrow M., Wohlenberg C., Becker M.H., Key G., Flad H.D., et al. The cell proliferation associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein associated with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123 (1993) 513-522
18. Mohseni H., Zaslau S., McFadden D., Riggs D.R., Jackson B.J., and Kanszari S. COX-2 inhibition demonstrates potent antiproliferative effects on bladder cancer in vitro. J Surg Res 119 (2004) 138-142
19. Yang C.Y., Meng C.L., Liao C.L., and Wong P.Y.K. Regulation of cell growth by selective COX-2 inhibitors in oral carcinoma cell lines. Prostaglandins Other Lipid Mediat 72 (2003) 115-130
20. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24 (2003) 96-102
21. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-inhibitor celecoxib. FASEB J 15 (2001) 2742-2744
22. Denkert C., Furstenberg A., Daniel P.T., Koch I., Kobel M., Weichert W., et al. Induction of G0/G1 arrest in ovarian cells by the anti-inflammatory drug NS-398, but not by COX-specific RNA interference. Oncogene 22 (2003) 8653-8661
23. Chen P.Y., and Long Q.C. Effects on cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin 25 (2004) 943-949
24. Smith E.R., Daly M.R., and Xiang-Xi X. A mechanism for COX-2 inhibitor anti-inflammatory activity in chemoprevention of epithelial cancers. Cancer Epidemiol Biomarkers Prev 23 (2004) 144-145